The Neuroendocrine Tumor Research Foundation (NETRF) is deeply grateful to Citizens of Humanity for donating $28,000 through the sale of The Lindz, a jean created
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter in cancer, especially when the name of an organ becomes
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Why do some neuroendocrine tumors grow slowly for years, while others progress more quickly? Researchers have
We recently spoke with John Metzcar, PhD, president of AMEND USA, neuroendocrine cancer patient and bioinformatics researcher. Can you share a little bit about yourself
By Anna Greene, PhD, Chief Scientific Officer, Neuroendocrine Tumor Research Foundation At NETRF, we often talk about the importance of funding foundational science. These studies
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Clinical trial news in neuroendocrine cancer is moving quickly. In this roundup, we highlight recent developments
By Anna C. Greene, PhD, NETRF Chief Scientific Officer When someone is diagnosed with metastatic neuroendocrine cancer, one of the most confusing questions can be:
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Patients often hear similar-sounding terms: neuroendocrine tumor, neuroendocrine carcinoma, NET, NEC, high-grade, poorly differentiated, well-differentiated. It
NETRF BOSA Leadership Transition The Neuroendocrine Tumor Research Foundation is pleased to share updates on the leadership and membership of its Board of Scientific Advisors
By Jessica Thomas, LCSW Director of Patient Education, NETRF For many people living with neuroendocrine cancer, the journey begins with a singular focus: survival. A